SkylineDx's Merlin CP-GEP Test outperforms competitor test in melanoma risk stratification, showing stronger predictive accuracy for SLNB outcomes.
Recent data analysis has debunked inaccurate benchmarks released by a competitor, with SkylineDx's separate analysis showcasing that the Merlin CP-GEP Test offers more robust metastatic-risk stratification and better predictive accuracy for SLNB outcomes compared to the 31-GEP/i31-SLNB method. This was found through a comprehensive evaluation...
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments